JPRN-jRCT2031220507Active, not recruitingPhase 1
A Phase 1 Clinical Study to Evaluate the Bioavailability of Pembrolizumab via Subcutaneous Injection of MK-3475A, a Formulation of Pembrolizumab With MK-5180, in Participants with Advanced Solid Tumors
Koh Yasuhiro0 sites96 target enrollmentStarted: December 13, 2022Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 96
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 18age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •Has histologically- or cytologically-confirmed diagnosis of Non Small Cell Lung Cancer (NSCLC) (Arm 3).
- •-Can provide archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated.
- •-Has a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
- •-Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group Performance Scale.
- •-Demonstrates adequate organ function.
Exclusion Criteria
- •-Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication.
- •-Has had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) before the first dose of study intervention, or has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from any adverse events (AEs) that were due to cancer therapeutics administered more than 4 weeks earlier (this includes participants with previous immunomodulatory therapy with residual immune-related AEs).
- •-Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
- •-Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •-Has severe hypersensitivity (>=Grade 3) to pembrolizumab and/or any of its excipients.
- •-Has an active infection requiring therapy.
- •-Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
- •-Has an active autoimmune disease that has required systemic treatment in the past 2 years.
- •-Has known hepatitis B or C infections or known to be positive for hepatitis B surface antigen (HBsAg)/hepatitis B virus deoxyribonucleic acid (DNA) or hepatitis C antibody or ribonucleic acid (RNA)
- •-Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
- •-Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
- •-Is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study.
- •-Has not fully recovered from any effects of major surgery without significant detectable infection.
- •-Has symptomatic ascites or pleural effusion.
- •-Has preexisting peripheral neuropathy that is >Grade 2 by latest NCI CTCAE version 5.
- •-Has a known sensitivity to recombinant hyaluronidase or other form of hyaluronidase.
- •-Has a history of severe hypersensitivity reaction (eg, generalized rash/erythema, hypotension, bronchospasm, angioedema, or anaphylaxis) to pemetrexed, cisplatin, axitinib, carboplatin, paclitaxel, or nab-paclitaxel.
- •-Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A study to compare a pediatric tablet or suspension of elvitegravir verses the adult 150 mg tablet in healthy adult volunteersHuman Immunodeficiency Virus (HIV-1) InfectionMedDRA version: 17.1Level: LLTClassification code 10020192Term: HIV-1System Organ Class: 100000004862EUCTR2015-000725-37-Outside-EU/EEAGilead Sciences, Inc.78
Completed
Phase 1
A study to determine the relative bioavailability of ACH-0144471 after administration of a tablet or softgel and capsule vs. a liquid filled capsule in healthy volunteers.Complement-mediated diseasesInflammatory and Immune System - Autoimmune diseasesACTRN12616001017415Achillion Pharmaceuticals Inc.26
Completed
Phase 1
A phase I study to compare the bioavailability and pharmacokinetics of fentanyl after administration of a single dose of a Fentanyl MDTS and a Durogesic 25 patch in paiPainOther - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)ACTRN12605000526673Acrux DDS Pty Ltd6
Active, not recruiting
Not Applicable
Pilot clinical study on the systemic bioavailability of l-thyroxine in healthy female volunteers after four weeks of topical treatment with a new formulation based on l-thyroxine - SOMA-001-2010treatment of localized fat, accompanied by celluliteMedDRA version: 14.1Level: LLTClassification code 10065339Term: CelluliteSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-023918-30-ITSOCIETA' ITALO BRITANNICA L. MANETTI - H.ROBERTS & C. PER AZIONI20
Active, not recruiting
Not Applicable
A Pilot Study to Evaluate the Relative Bioavailability of Diclofenac as Measured by Microdialysis After Repeated Doses of Two Topical Diclofenac Formulations - A Pilot Study to Evaluate the Relative Bioavailability of Two Topical Diclofenac Formulationsot applicable as this study is to compare the extent of absorption of two topical gels.EUCTR2007-005486-34-ATGlaxoSmithKline Consumer Healthcare